The grades of six Medical Devices stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
This week, ICU Medical (NASDAQ:ICUI) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. ICU Medical develops, manufactures, and sells disposable medical connection systems for use in intravenous therapy applications. The stock price has risen 8.1% over the past month, better than the 4% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ICUI stock.
This week, Endologix (NASDAQ:ELGX) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). Endologix develops, manufactures, sells, and markets minimally invasive treatments for vascular diseases. Shares of the company are up 2.5% from a month ago. For more information, get Portfolio Grader’s complete analysis of ELGX stock.
Teleflex‘s (NYSE:TFX) ratings are looking better this week, moving up to a B from last week’s C. Teleflex offers healthcare providers medical technology products that enable them to improve patient outcomes, reduce infections and enhance patient and provider safety. Investors have pushed the stock price up 7.5% over the past month. For more information, get Portfolio Grader’s complete analysis of TFX stock.
This is a strong week for Exactech (NASDAQ:EXAC). The company’s rating climbs to B from the previous week’s C. Exactech develops, manufactures, markets, and sells orthopedic implant devices and related surgical instrumentation. Over the last month, the price of EXAC shot up 3.1%. For more information, get Portfolio Grader’s complete analysis of EXAC stock.
ResMed Inc. (NYSE:RMD) is seeing ratings go up from a B last week to an A this week. ResMed develops, manufactures and distributes medical equipment for treating, diagnosing and managing sleep-disordered breathing and other respiratory disorders. Wall Street has pushed the stock higher by 10.9% over the past month. For more information, get Portfolio Grader’s complete analysis of RMD stock.
This week, Derma Sciences‘s (NASDAQ:DSCI) ratings are up from a C last week to a B. Derma Sciences markets and sells a range of skin care, wound management, and specialty securement devices. DSCI shares are up 0.9% from a month prior. For more information, get Portfolio Grader’s complete analysis of DSCI stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.